Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 883

1.

Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA.

McNeal MM, Stone SC, Basu M, Bean JA, Clements JD, Hendrickson BA, Choi AH, Ward RL.

Virology. 2006 Mar 15;346(2):338-47.

3.

Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge.

McNeal MM, Basu M, Bean JA, Clements JD, Lycke NY, Ramne A, Löwenadler B, Choi AH, Ward RL.

Vaccine. 2007 Aug 14;25(33):6224-31.

PMID:
17629371
4.

The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.

Choi AH, McNeal MM, Flint JA, Basu M, Lycke NY, Clements JD, Bean JA, Davis HL, McCluskie MJ, VanCott JL, Ward RL.

Vaccine. 2002 Mar 15;20(13-14):1733-40.

PMID:
11906760
5.

Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.

Choi AH, McNeal MM, Basu M, Flint JA, Stone SC, Clements JD, Bean JA, Poe SA, VanCott JL, Ward RL.

Vaccine. 2002 Sep 10;20(27-28):3310-21.

PMID:
12213401
6.

Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates.

VanCott JL, Prada AE, McNeal MM, Stone SC, Basu M, Huffer B Jr, Smiley KL, Shao M, Bean JA, Clements JD, Choi AH, Ward RL.

J Virol. 2006 May;80(10):4949-61.

8.

Development of a Bacillus subtilis-based rotavirus vaccine.

Lee S, Belitsky BR, Brinker JP, Kerstein KO, Brown DW, Clements JD, Keusch GT, Tzipori S, Sonenshein AL, Herrmann JE.

Clin Vaccine Immunol. 2010 Nov;17(11):1647-55. doi: 10.1128/CVI.00135-10.

9.
10.
12.
13.

Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies.

García-Díaz A, López-Andújar P, Rodríguez Díaz J, Montava R, Torres Barceló C, Ribes JM, Buesa J.

Vaccine. 2004 Dec 9;23(4):489-98.

PMID:
15530697
14.

IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein.

McNeal MM, Stone SC, Basu M, Clements JD, Choi AH, Ward RL.

Viral Immunol. 2007 Dec;20(4):571-84.

PMID:
18158731
15.

Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.

Parez N, Fourgeux C, Mohamed A, Dubuquoy C, Pillot M, Dehee A, Charpilienne A, Poncet D, Schwartz-Cornil I, Garbarg-Chenon A.

J Virol. 2006 Feb;80(4):1752-61.

16.

Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice.

Choi AH, Basu M, McNeal MM, Bean JA, Clements JD, Ward RL.

Protein Expr Purif. 2004 Dec;38(2):205-16. Erratum in: Protein Expr Purif. 2007 May;53(1):238.

PMID:
15555936
18.

Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.

Boyaka PN, Ohmura M, Fujihashi K, Koga T, Yamamoto M, Kweon MN, Takeda Y, Jackson RJ, Kiyono H, Yuki Y, McGhee JR.

J Immunol. 2003 Jan 1;170(1):454-62.

20.

Immune responses and protection obtained with rotavirus VP6 DNA vaccines given by intramuscular injection.

Yang K, Wang S, Chang KO, Lu S, Saif LJ, Greenberg HB, Brinker JP, Herrmann JE.

Vaccine. 2001 Apr 30;19(23-24):3285-91.

PMID:
11312027
Items per page

Supplemental Content

Support Center